Ajanta Pharma USA Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Ajanta Pharma USA Inc Pharmaceutical Import Records from India — 3 Products, $471.4K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ajanta Pharma USA Inc — Pharmaceutical Importer Profile (2026) | 3 Products, $471.4K Trade | TransData Nexus

Ajanta Pharma USA Inc

Pharmaceutical Importer · United States · Advanced Antifungals Focus · $471.4K Total Trade · DGFT Verified

Ajanta Pharma USA Inc is a pharmaceutical importer based in United States with a total trade value of $471.4K across 3 products in 3 therapeutic categories. Based on 13 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Ajanta Pharma USA Inc sources from 1 verified Indian supplier, with Ajanta Pharma Limited accounting for 100.0% of imports.

Ajanta Pharma USA Inc — Import Portfolio & Supplier Network

Ajanta Pharma USA Inc import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Ajanta Pharma USA Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Ajanta Pharma Limited	$31.2M	1,669	100.0%

Ajanta Pharma USA Inc sources from 1 verified Indian supplier across 917 distinct formulations. The sourcing is highly concentrated — Ajanta Pharma Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Ajanta Pharma USA Inc Import?

Formulation	Value	Ships
Duloxetine delayed release capsules 60MG	$1.4M	29
Oxybutynin chloride extended-release TAB	$1.1M	45
Duloxetine delayed release capsules 30MG	$800.0K	16
Duloxetine delayed release capsules 20MG	$705.7K	15
Divalproex sodium delayed release	$545.2K	12
Metformin hydrochloride extended	$461.8K	22
Cholestyramine for oral suspension USP	$440.1K	10
Duloxetine delayed release capsules 40MG	$413.7K	19
Amlodipine 5MG and olmesartan	$355.8K	38
Clonidine hydrochloride er tablets 0.1MG	$346.2K	14
Amlodipine 10MG and olmesartan	$312.4K	38
Pantoprazole sodium for delayed	$300.0K	6
Sildenafil tablet 100MG[76476pacx1x30=22	$200.0K	4
Fenofibrate tablets USP 160MG[33,252 x	$200.0K	4
Entacapone tablets 200MG[10908pacx1x100=	$200.0K	4

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Voriconazole	Advanced Antifungals	$250.0K	5	0.8%	12
2	Oseltamivir	Antivirals	$150.0K	3	0.1%	11
3	Captopril	Cardiovascular	$71.4K	5	0.6%	10

Ajanta Pharma USA Inc imports 3 pharmaceutical products across 3 categories into United States totaling $471.4K.

Ajanta Pharma USA Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Ajanta Pharma USA Inc., headquartered in Bridgewater, New Jersey, is a wholly owned subsidiary of Ajanta Pharma Limited, an Indian multinational pharmaceutical company established in 1973. Ajanta Pharma USA is dedicated to delivering high-quality generic drugs to the U.S. market, focusing on a portfolio that includes immediate-release, extended-release, delayed-release, and fixed-dose formulations. The company emphasizes superior service, supply chain reliability, and flexibility to meet the unique needs of its customers.

As of December 30, 2025, Ajanta Pharma USA has received 50 Abbreviated New Drug Application (ANDA) approvals, with 49 products commercialized. The company plans to file 8-12 ANDAs annually, reflecting its commitment to expanding its presence in the U.S. generics market.

2Distribution Network

Ajanta Pharma USA's distribution network is centered in Bridgewater, New Jersey, serving as the primary hub for its U.S. operations. While specific warehouse locations and logistics capabilities are not publicly detailed, the company's strategic position in New Jersey provides advantageous access to major transportation routes, facilitating efficient distribution across the United States. Ajanta Pharma USA collaborates with major distributors to ensure a reliable supply chain, demonstrating flexibility and responsiveness to market demands.

3Industry Role

Ajanta Pharma USA Inc. operates as a pharmaceutical importer and distributor within the U.S. market. By importing finished pharmaceutical formulations from its parent company, Ajanta Pharma Limited, the subsidiary plays a crucial role in supplying generic medications to various stakeholders, including wholesalers, distributors, and healthcare providers. The company's focus on quality and reliability has strengthened its position as a partner of choice in the U.S. generics market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Ajanta Pharma USA Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Ajanta Pharma USA's sourcing strategy is highly concentrated, with all its imports originating from a single supplier: Ajanta Pharma Limited. This single-source dependency indicates a strategic choice to maintain control over product quality and supply chain consistency. The substantial volume of imports—totaling $471,000 across 13 shipments—suggests a stable and reliable relationship between the subsidiary and its parent company. However, this concentration also exposes Ajanta Pharma USA to potential risks associated with supply chain disruptions or changes in the supplier's operational capacity.

2Supply Chain Resilience

Ajanta Pharma USA's supply chain resilience is closely tied to its relationship with Ajanta Pharma Limited. The parent company's seven manufacturing facilities in India, including those approved by the U.S. FDA, provide a robust foundation for consistent product quality and availability. While the reliance on a single supplier streamlines operations, it also necessitates contingency planning to mitigate risks associated with potential disruptions. The company's commitment to maintaining an industry-leading inventory position of finished goods demonstrates proactive measures to ensure supply continuity.

Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing pharmaceutical imports. Key legislation governing these imports includes the Federal Food, Drug, and Cosmetic Act, which sets forth requirements for drug safety, efficacy, and quality. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating and approving new drugs, including generics, through the Abbreviated New Drug Application (ANDA) pathway. This regulatory framework ensures that imported pharmaceutical products meet the necessary standards for public health and safety.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. market are stringent. Manufacturers must obtain FDA approval for each product, demonstrating compliance with Good Manufacturing Practice (GMP) standards. The FDA recognizes GMP certifications from reputable authorities, including the European Medicines Agency (EMA), World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Additionally, wholesale distributors must obtain authorization from the FDA, ensuring that all entities in the supply chain adhere to regulatory standards.

Quality & Labeling

Ajanta Pharma USA Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Ajanta Pharma USA's product strategy focuses on a selective approach to the U.S. generics market, emphasizing the launch of limited competition products. The company's portfolio includes immediate-release, extended-release, delayed-release, and fixed-dose formulations, catering to a diverse range of therapeutic areas. This strategy is driven by market demand for differentiated products and the company's commitment to addressing unmet medical needs.

2Sourcing Profile

Ajanta Pharma USA's sourcing strategy is centered on importing finished pharmaceutical formulations from its parent company, Ajanta Pharma Limited. This approach ensures consistency in product quality and supply chain reliability. The company's focus on generic drug sourcing aligns with its mission to provide cost-effective solutions to the U.S. market, leveraging India's manufacturing capabilities and expertise in generic drug production.

3Market Positioning

Based on its product mix, Ajanta Pharma USA serves various segments of the U.S. pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's emphasis on quality, reliability, and customer service positions it as a preferred partner for healthcare providers and distributors seeking dependable generic pharmaceutical products.

Seller's Guide — How to Become a Supplier to Ajanta Pharma USA Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the U.S. market by meeting the stringent regulatory requirements set by the FDA and aligning with the quality standards expected by companies like Ajanta Pharma USA. Gaps in Ajanta Pharma USA's current sourcing may exist in specific therapeutic areas or product formulations, presenting potential avenues for new suppliers to address unmet needs.

2Requirements & Qualifications

Indian exporters seeking to supply Ajanta Pharma USA and the U.S. market must obtain FDA approval for each product, demonstrating compliance with GMP standards recognized by the FDA. Manufacturing facilities must pass FDA inspections, and products must meet labeling and serialization requirements. Additionally, exporters should ensure that their products are listed in the FDA's Orange Book, confirming their eligibility for sale in the U.S. market.

3How to Approach

To build a relationship with Ajanta Pharma USA, Indian exporters should initiate contact through formal channels, presenting their product portfolios and demonstrating compliance with FDA regulations. Participating in tenders and responding to Requests for Proposals (RFPs) can provide opportunities to showcase product offerings. Developing a regulatory filing strategy that aligns with FDA requirements and establishing a clear timeline for product approvals are essential steps in entering the U.S. market.

Frequently Asked Questions — Ajanta Pharma USA Inc

What products does Ajanta Pharma USA Inc import from India?

Ajanta Pharma USA Inc imports 3 pharmaceutical products across 3 categories. Top imports: Voriconazole ($250.0K), Oseltamivir ($150.0K), Captopril ($71.4K).

Who supplies pharmaceuticals to Ajanta Pharma USA Inc from India?

Ajanta Pharma USA Inc sources from 1 verified Indian suppliers. The primary supplier is Ajanta Pharma Limited (100.0% of imports, $31.2M).

What is Ajanta Pharma USA Inc's total pharmaceutical import value?

Ajanta Pharma USA Inc's total pharmaceutical import value from India is $471.4K, based on 13 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Ajanta Pharma USA Inc focus on?

Ajanta Pharma USA Inc imports across 3 categories. The largest: Advanced Antifungals (53.0%), Antivirals (31.8%), Cardiovascular (15.2%).

Get Full Ajanta Pharma USA Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.